Close

Form 8-K Jazz Pharmaceuticals For: Jan 11

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. META
6. BA
7. V
8. IBM
9. KMB
10. HCP


January 12, 2016 4:20 PM EST



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

January 11, 2016
Date of Report (Date of earliest event reported)
 
 
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact Name of Registrant as Specified in Charter)
 
 
 
 
 
 
 
Ireland
 
001-33500
 
98-1032470
(State or Other Jurisdiction of Incorporation)
 
(Commission File No.)
 
(IRS Employer Identification No.)
 
 
Fourth Floor, Connaught House
1 Burlington Road, Dublin 4, Ireland
(Address of principal executive offices, including zip code)

011-353-1-634-7800
 
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


Item 2.02. Results of Operations and Financial Condition.

On January 11, 2016, at the J.P. Morgan Healthcare Conference in San Francisco, California, Jazz Pharmaceuticals plc (the “Company”) presented a corporate overview and financial update, which presentation included the Company’s current expectations with respect to certain operating results for the year ended December 31, 2015. The presentation was announced by a widely disseminated press release and was made available to the public by audio webcast, and the slides that accompanied the presentation were made available to the public on the Company’s website. A transcript of the relevant portion of the presentation relating to the aforementioned financial update is attached hereto as Exhibit 99.1, along with a copy of the relevant slides containing such information.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.
Exhibits
Exhibit Number
 
Description
99.1
 
Portion of transcript and related slides of presentation by Jazz Pharmaceuticals plc on January 11, 2016



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
 
 
 
 
By:
/s/ Matthew P. Young
 
 
Matthew P. Young
 
 
Executive Vice President and Chief Financial Officer

Date: January 12, 2016





EXHIBIT INDEX

Exhibit Number
 
Description
99.1
 
Portion of transcript and related slides of presentation by Jazz Pharmaceuticals plc on January 11, 2016






Exhibit 99.1

Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 11, 2016:

Bruce C. Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc
…
2015 was a very significant year for our company. Good top- and bottom-line growth.
…
I will point out I will make forward-looking statements today. Actual results may differ materially and, obviously, forward-looking statements are subject to risks and uncertainties that we detail in our SEC filings.
…
Finally, I will refer to guidance in this presentation. That guidance is as we presented it on November 9 and it is as of that date, unless I specifically update it today.
…
With reference to slide 3: For 2015, we do expect to meet our prior guidance on the top line. That would represent about 13% or 14% top-line growth over 2014 with most of that growth and most of those revenues coming, as you can see in the pie chart on the right, from our core products.
…
With reference to slide 4: 2015 was a record year for us, both in terms of patients on drug and bottles shipped, but the year was significantly impacted by the implementation of our REMS starting in the third quarter. Pharmacy operations have stabilized and we believe the REMS implementation is behind us. We did end the year with 6% volume growth and we do expect to meet our financial revenue guidance for the year.
…
With reference to slide 5: We expect our Erwinaze revenues will also meet our prior guidance of $200 million to $210 million in sales for 2015.
…
With reference to slide 6: We do expect to meet our guidance on revenues for Defitelio for 2015.
…




Relevant slides from Jazz Pharmaceuticals plc's presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 11, 2016:































Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings